Next, in order to determine whether Csn-B treatment can control IAV infection, infected mice were treated daily with increasing doses of NR4A1 agonist post-infection and lung viral loads were assessed at day 5 post-infection, which corresponds to the highest replicative activity of IAV [26]. This evidence concerns the gene NR4A1 and infection.